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For the past decade protein acetylation has been shown to be a crucial post-transcriptional
modification involved in the regulation of protein functions. Histone acetyltransferases
(HATs) mediate acetylation of histones which results in the nucleosomal relaxation
associated with gene expression. The reverse reaction, histone deacetylation, is mediated
by histone deacetylases (HDACs) leading to chromatin condensation followed by
transcriptional repression. HDACs are divided into distinct classes: I, IIa, IIb, III, and IV,
on the basis of size and sequence homology, as well as formation of distinct repressor
complexes. Implications of HDACs in many diseases, such as cancer, heart failure, and
neurodegeneration, have identified these molecules as unique and attractive therapeutic
targets. The emergence of HDAC4 among the members of class IIa family as a major
player in synaptic plasticity raises important questions about its functions in the brain. The
characterization of HDAC4 specific substrates and molecular partners in the brain will not
only provide a better understanding of HDAC4 biological functions but also might help
to develop new therapeutic strategies to target numerous malignancies. In this review
we highlight and summarize recent achievements in understanding the biological role of
HDAC4 in neurodegenerative processes.
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INTRODUCTION
Transcription is a multistep process and its regulation involves
a balanced coordination of several molecular factors. Epigenetic
modifications of chromatin, including histone acetylation, rep-
resent priming events in the cascade leading to gene expression
and are governed by the antagonistic activity of two families
of enzymes: the histone acetyltransferases (HATs) and histone
deacetylases (HDACs) (Fischer et al., 2010). The covalent mod-
ification of conserved lysine residues within histone proteins by
acetyl groups leads to a nucleosomal relaxation and transcrip-
tional activation; this reversible process provides a central mech-
anism to control gene expression and cellular signaling events.
As such HDACs mediate epigenetic mechanisms that play a key
role in homeostasis of histone functions and gene transcription.
Mammalian HDACs are a family of 18 proteins divided into four
groups based on structural and functional similarities: class I
(HDACs: 1, 2, 3, 8), class IIa (HDACs: 4, 5, 7, 9), class IIb (HDACs:
6, 10), class III (sirtuins 1-7), and HDAC11 as the sole mem-
ber of class IV (Saha and Pahan, 2006). It is well established that
HDACs alter cell growth and differentiation by either governing
chromatin structure or repressing the activity of specific tran-
scription factors (Fischer et al., 2010). They are often deregulated
in diseases and inhibition of their enzymatic activities remains of
therapeutic interest.
Interestingly, the class IIa subgroup of HDACs shows a num-
ber of unique features in comparison to other HDACs (Verdin
et al., 2003). Unlike the class I enzymes that are predominantly
localized in the nucleus, class IIa HDACs shuttle between the
nucleus and cytoplasm, a process that is controlled through
the phosphorylation of specific serine residues (Chawla et al.,
2003). The class IIa members are potent transcriptional repres-
sors due to a high interaction propensity of N-terminal domains
toward tissue specific transcription factors (Petrie et al., 2003;
Saha and Pahan, 2006). Finally, the C-terminal catalytic domain
of class IIa enzymes is characterized by a unique mutation of
Tyr residue into His leading to the deacetylase domain inactiva-
tion (Lahm et al., 2007), emphasizing their distinctive properties
compared to other HDACs (Verdin et al., 2003; Saha and Pahan,
2006).
HDAC4 shows approximately 60–70% sequence identity to
HDAC5 and HDAC7 (de Ruijter et al., 2003). Among class IIa
HDACs, HDAC4 has been described as a potent transcriptional
repressor that is able to interact via its N-terminal domain with
many different co-repressors, specifically in the brain. Hence,
HDAC inhibitors have been recently used in the treatment of
a wide-range of brain disorders characterized by pathologi-
cal alterations in the transcriptome (Fischer et al., 2010) and
they have displayed neuroprotective effects in animal models
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of such neurological disorders like Huntington’s disease (HD),
Alzheimer’s disease (AD) and ischemic stroke.
REGULATION OF HDAC4 EXPRESSION, CELLULAR
LOCALIZATION AND FUNCTION
HDAC4 is ubiquitously expressed throughout the body with
enrichment in the brain, heart and skeletal muscle (Verdin et al.,
2003; Broide et al., 2007). However, the transcriptional mecha-
nisms involved in the regulation of HDAC4 expression are poorly
understood. Recent studies have shown that HDAC4 expression
might be tightly regulated by microRNAs. In podocytes, miR-29a
reduced HDAC4 signaling and attenuated the glucocorticoid-
mediated β-catenin deacetylation and ubiquitination (Ko et al.,
2013; Lin et al., 2014). Similarly, miR-365 reduced endogenous
HDAC4 protein levels and led to inhibition of chondrocyte dif-
ferentiation (Guan et al., 2011). Overexpression or inhibition of
miR-206 in skeletal muscles has been associated with a decrease
or increase of endogenous HDAC4 levels, respectively (Williams
et al., 2009; Liu et al., 2012; Winbanks et al., 2013). HDAC4
expression has also been reported to be up-regulated under ER
stress through its interaction with activating transcription factor
4 (ATF4). In vitro, HDAC4 overexpression caused ATF4 cyto-
plasmic retention and inhibition of ATF4 transcriptional activity,
suggesting the presence of an autoregulatory loop. ER stress
can ultimately promote cell apoptosis through up-regulation of
ATF4 target genes such as CHOP and TRB3 and this effect was
exacerbated by HDAC4 down-regulation (Zhang et al., 2014).
It is believed that HDAC4 undergoes a signal-dependent shut-
tling between the cytoplasm and nucleus, although in the brain
it seems to be exclusively localized to the cytoplasm (Darcy
et al., 2010; Mielcarek et al., 2013a,b). This nuclear-cytoplasmic
shuttle is controlled by multiple mechanisms including activity
of calcium/calmodulin-dependent kinase (CaMK) (Bolger and
Yao, 2005) and salt-inducible kinases (Walkinshaw et al., 2013a),
cAMP signaling (Walkinshaw et al., 2013b), and oxidative stress
(Matsushima et al., 2013) (reviewed in Parra and Verdin, 2010,
Figure 1A). Under normal conditions phosphorylated HDAC4
was retained in the cytoplasm through its association with 14-3-3
proteins (Grozinger and Schreiber, 2000; Verdin et al., 2003),
(Figure 1A) and once dephosphorylated at Ser298 by the cat-
alytic subunit of PP2A (Protein Phosphatase 2) it moved into the
nucleus (Paroni et al., 2008).
It has been shown that HDAC4 can produce three specific
nuclear pools including full length HDAC4 and two N-terminal
fragments with different functions controlling cell death and
differentiation in vitro (Paroni et al., 2004, 2007; Backs et al.,
2011). Indeed, HDAC4 protein can be cleaved by caspases lead-
ing to a HDAC4-nuclear fragment generation (Paroni et al., 2004,
2007). Cleavage of HDAC4 occurred at Asp289 and resulted
in the formation of a cytosolic carboxy-terminal fragment and
an amino-terminal fragment that accumulated into the nucleus.
This nuclear fragment exhibited a stronger cell death-promoting
activity coupled with increased repressive effect on Runx2 (Runt-
related transcription factor 2) or SRF (Serum response factor)
dependent transcription. Interestingly, this nuclear fragment was
a less potent inhibitor of MEF2C (Myocyte enhance factor 2C)-
driven transcription, compared to full-length HDAC4 (Paroni
et al., 2004), although such repressor activity has been described
as independent from the acetylase domain. While caspase-2 and
caspase-3 have been shown to cleave HDAC4 in vitro, caspase-3
was critical for HDAC4 cleavage in vivo during UV-induced apop-
tosis (Paroni et al., 2004). In the nucleus, a caspase-generated
HDAC4 fragment was also reported to trigger cytochrome
C release from mitochondria and cell death in a caspase-9-
dependent manner (Liu and Schneider, 2013). In isolated skeletal
muscle fibers expressing a HDAC4-green fluorescent protein,
activation of PKA by the beta-receptor agonist isoproterenol or
dibutyryl cAMP caused a steady HDAC4 nuclear influx. Thus,
mutations of Ser265 and Ser266 (PKA targeted serines) enabled
HDAC4 to respond to PKA activation (Liu and Schneider,
2013). Similarly, clenbuterol a potent β2-adrenoreceptor stimula-
tor in skeletal muscles caused HDAC4 phosphorylation on Ser246
through activation of CaMKII (Ohnuki et al., 2014). In car-
diomyocytes, PKA induced generation of the N-terminal HDAC4
cleavage product at Tyr202. This N-terminal fragment selectively
inhibits activity of MEF2 but not SRF, thereby antagonizing a
pro-hypertrophic potential of CaMKII signaling without affect-
ing cardiomyocytes survival. Thus, HDAC4 may function as a
molecular nexus for the antagonistic actions of the CaMKII and
PKA pathways (Backs et al., 2011). In addition, sustained gly-
colysis induced by lipopolysaccharide (LPS) treatment activated
caspase-3, which cleaved HDAC4 and triggered its degrada-
tion. Importantly, a caspase-3 resistant HDAC4 mutant escaped
LPS-induced degradation and prolonged inflammatory cytokine
production through the GSK3β (Glycogen Synthase Kinase-3 β
isoform)–iNOS (inducible Nitric Oxide Synthase)–NO (Nitric
Oxide) axis (Wang et al., 2014a). However, until now, there
have been no data available suggesting a similar proteolytic pat-
tern of HDAC4 in the healthy brain or in neurodegenerative
disorders.
Interestingly, cleavage and phosphorylation sites are all located
within the N-terminal region of HDAC4 protein highlighting this
area as an important regulatory domain. While this N-terminal
region seems to be critical for the repressive function of HDAC4,
it also contains a transcription factor interacting domain that can
bindMEF2 familymembers. HDAC4-MEF2 interaction was asso-
ciated with the inhibition of MEF2 function resulting in neuronal
cell death (Mao et al., 1999) and repression of MEF2-dependent
genes in neuronal cells (Bolger and Yao, 2005) and skeletal mus-
cles (Miska et al., 2001). In addition, the HDAC4 N-terminal
region is characterized by a high glutamine content that is likely
responsible for interactions with other glutamine-rich proteins
leading to a spontaneous assembly of insoluble toxic amyloid-like
structures (Fiumara et al., 2010). X-ray resolution of the human
HDAC4 glutamine-rich domain showed that this domain is pref-
erentially folding into a straight alpha-helix which assembles into
a tetramer. In contrast to the coiled coil proteins, the HDAC4
tetramer lacked the regular arrangement of apolar residues and
had an extended hydrophobic core that might lead to its rapid
equilibrium with monomer and intermediate species (Guo et al.,
2007). Overall, these studies provide a picture of a multifunc-
tional protein and emphasize the presence of several mechanisms
behind the tissue-specific regulation of HDAC4 expression and
function.
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REGULATION OF HDAC4 DEACETYLASE ACTIVITY
Previous findings have suggested that class IIa HDACs are inac-
tive on acetylated substrates, thus differing from class I and IIb
enzymes (de Ruijter et al., 2003). HDAC4 catalytic domain puri-
fied from bacteria was 1000-fold less active than class I HDACs
on standard substrates (Lahm et al., 2007). In contrast to the
other HDACs, the C-terminal catalytic domain of the class IIa
enzymes contains an amino acid substitution of a critical Tyr
residue into His (Lahm et al., 2007). Mutation of this Tyr to His
in class I HDACs severely reduced their activity, while a His-976-
Tyr mutation in HDAC4 produced an enzyme with a 1000-fold
higher catalytic efficiency (Lahm et al., 2007). Interestingly, muta-
tions in the residues involved either in the coordination of the
structural zinc binding domain of HDAC4 or the binding site of
class IIa selective inhibitors prevented the association of HDAC4
with N-CoR/HDAC3 associated repressor complex (Bottomley
et al., 2008). It has been proposed that HDAC4 binds directly to
HDAC3 in order to activate its deacetylase domain (Mihaylova
et al., 2011) and that the structural zinc-binding domain is crucial
in the regulation of class IIa HDAC functions (Bottomley et al.,
2008).
Finally, HDAC4 activity seems to be modulated by the
ubiquitin-proteasome system. Serum starvation elicited the
polyubiquitination and degradation of HDAC4 in non-
transformed cells. Phosphorylation of Ser298 within the PEST1
sequence, a GSK3β consensus sequence, played an important
role in the control of HDAC4 stability. Phosphorylation of
HDAC4 by GSK3β has been described to occur in vitro upon
phosphorylation of Ser302, which seems to play a role of a
priming phosphate (Cernotta et al., 2011) and removal of growth
factors fails to trigger HDAC4 degradation in cells deficient in
this kinase (Figure 1B). One might conclude that HDAC4 is not
a histone/protein deacetylase, however it can play a crucial role
in many processes through its interaction with HDAC3 or with a
general role of scaffolding protein.
HDAC4 BIOLOGICAL FUNCTION IN NON CNS ORGANS
As mentioned, HDAC4 is ubiquitously expressed, however, its
initial biological function was described in chondrocytes: direct
inhibition of RUNX2 by HDAC4 led to chondrocyte hypertro-
phy (Vega et al., 2004). HDAC4-null mice displayed premature
ossification of developing bones due to an ectopic and early
onset chondrocyte hypertrophy, mimicking the phenotype asso-
ciated with the constitutive Runx2 expression in chondrocytes.
On the other hand, overexpression of HDAC4 in proliferating
chondrocytes in vivo inhibited their hypertrophy and differentia-
tion, mimicking a Runx2 loss-of-function phenotype (Vega et al.,
2004).
HDAC4 has been described as a critical factor that connects
neural activity to the muscle remodeling program, nevertheless,
its role in the physiology of this peripheral tissue is controver-
sial and has not been entirely clarified. Inactivation of HDAC4
suppressed denervation-induced muscle atrophy while increased
re-innervation (Williams et al., 2009; Winbanks et al., 2013).
Although it has been observed that miR-206 could regulate
HDAC4 expression in skeletal muscles, the postnatal expression
of miR-206 is not a key regulator of a basal skeletal mus-
cles mass or specific pathways of muscle growth and wasting
(Winbanks et al., 2013). Previous studies established that mus-
cle denervation strongly induced the expression of Gadd45a,
FIGURE 1 | Continued.
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FIGURE 1 | Structure and cellular function of HDAC4. (A) Summary of
HDAC4 post translational modifications. CC, coil-coil domain; TBD,
transcription binding domain; NLS, nuclear localisation signal; NES, nuclear
export signal; DAC, deacetylation domain. (B) Summary underlying HDAC4
cellular localization and identified functions spanning all tested systems.
HDAC4 undergoes nuclear-cytoplasmic shuttling in response to different
stimuli through multiple kinases (1). In the cytoplasm, HDAC4 might be
cleaved by proteases (2) to generate a small N-terminal fragment that
translocates into the nuclei (3) to bind different transcription factors (TF) and
repress their driven transcription. Similarly the full length HDAC4 upon
dephosphorylation by phosphatases (4) translocates into the nuclei to act as
a repressor of TF. In the nuclei, HDAC4 is cleaved by unknown protease to
produce a distinct nuclear N-terminal fragment (5). Treatment with HDACIs
might lead to the RANBP2-mediated proteasome degradation of HDAC4 (6).
HDAC4 as a non-active deacetylase can also bind HDAC3 (7) to enhance its
deacetylase activity (8). HDAC4 as a scaffolding protein prompts to form
many complexes and has showed a cytosolic pro-aggregation propensity in
HD mouse models (9).
a small myonuclear protein that is required for denervation-
induced muscle fiber atrophy. Interestingly, it was shown that
HDAC4mediated an induction of Gadd45a mRNA in denervated
skeletal muscles (Bongers et al., 2013). Furthermore, HDAC4 has
been described to induce AP1-dependent transcription by acti-
vating the HDAC4-MAPK-AP1 signaling axis essential for the
neurogenic muscles atrophy (Choi et al., 2012). Interestingly,
AP1 inactivation recapitulates HDAC4 deficiency and blunts
the muscle’s atrophy program. Surprisingly, HDAC4 stimulated
AP1 activity by activating the HDAC4-MAPK-AP1 signaling axis
essential for the neurogenic skeletal muscles atrophy (Choi et al.,
2012). HDAC4 was also described as a member of the MEF2C
repressor complex together with HDAC3 and Ser/Thr kinase
homeodomain-interacting protein kinase 2 (HIPK2) in undiffer-
entiated myoblasts (de la Vega et al., 2013). On the other hand,
a recent study has shown that HDAC4 inactivation led to defec-
tive satellite cells proliferation, muscle regeneration and lipid
accumulation (Choi et al., 2014).
Finally, it was shown that HDAC4 up-regulation was sig-
nificantly greater in patients with rapidly progressive ALS
(Amyotrophic lateral sclerosis) and its expression was nega-
tively correlated with a degree of skeletal muscles re-innervation
and functional outcome (Bruneteau et al., 2013). Similarly an
increased level of HDAC4 has been found in SMA (Spinal mus-
cular atrophy) model mice and in SMA patient muscles (Bricceno
et al., 2012). Moreover, HDAC4 expression was increased in mas-
seter muscles from a patient with a deepbite and was found to
correlate negatively with slow myosin type I and positively with
fast myosin type IIX (Huh et al., 2013). Overall, these studies
provide evidence of an active role of HDAC4 in the neuro-
genic muscle’s atrophy program, which becomes exacerbated in
some neurodegenerative disorders, therefore, urging HDAC4 as a
promising therapeutic target.
HDAC4 FUNCTION IN THE BRAIN AND ITS IMPLICATION IN
NEURODEGENERATION
Compared to the other class IIa enzymes, HDAC4 is highly
expressed in the mouse brain (Grozinger et al., 1999; Darcy et al.,
2010) with a highest expression occurring during early postna-
tal life (Sando et al., 2012). Immunohistochemical analysis of
brain sections revealed accumulation of HDAC4 in the cytoplasm
of neurons, including neurons containing CRH, oxytocin, vaso-
pressin, orexin, histamine, serotonin, and noradrenaline (Takase
et al., 2013). HDAC4-immunoreactive puncta were uniform in
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size and were widely distributed in the neuropil of brain areas,
including the PVN (Hypothalamic Paraventricular Nucleus),
LHA (Lateral Hypothalamic Area), ARC (Hypothalamic Arcuate
Nucleus), TMN (Tuberomammillary Nucleus), DR (Dorsal
Raphe), and LC (Locus Coeruleus). Interestingly, these HDAC4
positive accumulations co-localized with PSD95-immunoreactive
puncta (Mielcarek et al., 2013a; Takase et al., 2013 ), suggest-
ing a role for HDAC4 in synaptic plasticity (Sando et al., 2012;
Mielcarek et al., 2013a).
In neurons, dynamic changes in the subcellular localiza-
tion of HDACs are thought to contribute to various signaling
pathways. Treatment with the neuronal survival factor BDNF
(Brain-derived neurotrophic factor) suppressed HDAC4 nuclear
translocation, whereas a pro-apoptotic CaMK inhibitor stim-
ulated HDAC4 nuclear accumulation. Moreover, as expected,
an ectopic expression of the nuclear-localized HDAC4 led to
neuronal apoptosis and repressed the transcriptional activities
of survival factors in neurons like: MEF2 and cAMP response
element-binding protein (CREB). In contrast, inactivation of
HDAC4 by small interfering RNA or HDAC inhibitors suppressed
neuronal cell death (Bolger and Yao, 2005). In cultured hip-
pocampal neurons, localization of HDAC4 has been shown to
be very dynamic and signal-regulated and spontaneous electrical
activity was sufficient for HDAC4 nuclear export (Chawla et al.,
2003). On the other hand, in various experimental models, it
has been shown that loss of HDAC4 could lead to neurodegen-
eration of the retina (Chen and Cepko, 2009) and cerebellum
(Majdzadeh et al., 2008). This might be explained by the chondro-
cyte hypertrophy that occurred in mice lacking HDAC4 causing
developmental brain abnormalities due to a skull deformation
(Vega et al., 2004) and might be further supported by major
pathological changes in the Hdac4 knock-out murine postnatal
brain (Majdzadeh et al., 2008). In addition, a conditional knock-
out ofHdac4 under the CamkII promoter in the mouse forebrain,
showed impairments in the hippocampal-dependent learning and
memory with a simultaneous increase in locomotor activity (Kim
et al., 2012). However, it was recently shown that a selective dele-
tion of Hdac4 under the control of the Thy1 or Nestin promoters
resulted in a normal gross brain morphology and cytoarchitec-
ture as well in a normal locomotor activity (Price et al., 2013).
Moreover, the Affymetrix array data showed no effect of Hdac4
knock-out on the transcriptional profile and global acetylation of
the postnatal murine brain (Mielcarek et al., 2013b). Similarly, a
hippocampal depletion of HDAC4 in vivo abolished long-lasting
stress-inducible behavioral changes and improved stress related
learning and memory impairments in mice (Sailaja et al., 2012).
HDAC4 overexpression has been shown to accelerate the death of
cerebellar granule neurons (Bolger and Yao, 2005; Li et al., 2012;
Sando et al., 2012) by increasing their vulnerability to H202 insult
due to an inhibition of PPARα activity (peroxisome proliferators-
activated receptor α) (Yang et al., 2011). In addition, the HDAC4
viral-mediated overexpression in the rat hippocampus was suf-
ficient to induce depression like behavior (Sarkar et al., 2014).
Interestingly, overexpression of HDAC4 in the adult mushroom
body, an important structure for memory formation, resulted in
a specific impairment in long-term courtship memory but had
no affect on short-termmemory inDrosophilamodel (Fitzsimons
et al., 2013). Similarly, HDAC4 and HDAC5 increased a cell via-
bility through an inhibition of HMGB1, a central mediator of
tissue damage following acute injury and it has been shown that
NADPH oxidase-mediated HDAC4 and HDAC5 expression con-
tributed to the cerebral ischemia injury through the HMGB1
signaling pathway that could be an effective therapeutic target to
treat stroke (He et al., 2013).
HDAC INHIBITORS AND INHIBITION OF HDAC4 ACTIVITY
Suberoylanilide hydroxamic acid, known also as SAHA or vorino-
stat, was the first HDAC inhibitor (HDACI) to be approved for the
cancer therapy of advanced cutaneous T-cell lymphoma (Marks
and Breslow, 2007). Initially, SAHA was identified as an inhibitor
of class I and class II HDACs at nanomolar concentrations
(Richon et al., 1998), but was further characterized as inhibitor
of class I HDACs as well specifically HDAC6 within the class
IIb enzyme (Parmigiani et al., 2008; Marks and Xu, 2009). More
recently activity based probes have been used to demonstrate that
SAHA can bind directly to both class I and IIa HDACs (Salisbury
and Cravatt, 2007; Codd et al., 2009). Experiments performed on
cancer cell lines revealed the ability of SAHA to induce the degra-
dation via RANBP2-mediated proteasome of both HDAC4 and
HDAC5 in vitro (Scognamiglio et al., 2008). Interestingly, other
HDACIs, such as trichostatin A (TSA) and sodium butyrate, have
also been reported to induce a reduction in HDAC4 levels when
administered to embryoid bodies (Chen et al., 2011), suggesting
that similarly to SAHA, these other HDACIs could induceHDAC4
degradation through a proteasome-dependent mechanism.
An increased expression of HDAC4 has been described in sev-
eral in vitro and in vivomodels of neuro-like disorders. Treatment
of neuronal cell lines with SAHA led to a noticeable improve-
ment of cell polarity and morphology, with longer processes in
the rat H19-7 hippocampal cell line with folate deficiency. In this
neuronal cell model, folate deficit led to a reduction in cell prolif-
eration and decreased production of S-adenosylmethionine (the
universal substrate for transmethylation reactions) concurrent
with an increased expression of HDACs (including HDAC4,6,7)
(Akchiche et al., 2012). Furthermore, cecal ligation and perora-
tion (CLP) rats, used in the Sepsis-associated encephalopathy
(SAE) study, were also characterized by an increased expres-
sion of HDAC4 (Fang et al., 2014). Administration of HDACIs
(e.g., TSA or SAHA) restored Bcl-XL and Bax levels in vivo and
decreased apoptotic cells in vitro. In addition, knock-down of
HDAC4 by shRNA resulted in an enhanced histone acetylation
like: H3 and H4 and reduced neuronal apoptosis. Consistently,
CLP rats treated with TSA or SAHA exhibited significant spatial
learning and memory deficits with no effect on their locomotive
activity (Fang et al., 2014).
In preclinical settings, SAHA and other HDACIs have consis-
tently improved the phenotype in HD mouse models (Ferrante
et al., 2003; Hockly et al., 2003; Gardian et al., 2005) and are being
developed as HD therapeutics. Recent findings have increas-
ingly described a widespread peripheral organ pathology in HD,
such as skeletal muscles atrophy (Zielonka et al., 2014a) and
heart failure (Mielcarek et al., 2014a; Zielonka et al., 2014b),
often associated with an increased HDAC4 expression (Mielcarek
et al., 2014b). As such, class IIa HDACs inhibitors might be
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beneficial in delaying HD-related symptoms and, therefore, are
under evaluation as HD therapeutics. It has been shown that the
administration of SAHA to wild type and R6/2 mice decreased
HDAC2 andHDAC4 at the protein but not RNA levels in different
brain regions in vivo (Mielcarek et al., 2011), supporting previous
observations from cancer cell lines (Scognamiglio et al., 2008).
We have also shown that HDAC4 associates with huntingtin in
a polyglutamine-length dependent manner and co-localizes with
cytoplasmic inclusions. Consequently, reduction of HDAC4 lev-
els delayed cytoplasmic aggregate formation in different brain
regions of R6/2 mice and rescued cortico-striatal neuronal synap-
tic function in HD mouse models. This was accompanied by an
improvement in motor co-ordination, neurological phenotypes
and increased lifespan (Mielcarek et al., 2013a). Interestingly,
SAHA treatment of R6/2 mice was accompanied by restora-
tion of brain-derived neurotrophic factor (BDNF) cortical tran-
script levels (Mielcarek et al., 2011). An increased expression of
BDNF has been associated with memory-enhancing and neu-
roprotective properties of HDACIs, as it has been shown that
HDAC4 and HDAC5 might repress specific Bdnf transcripts in
rats and primary hippocampal neuronal cultures and this effect
was reversed by SAHA treatment (Koppel and Timmusk, 2013).
However, the mechanism of BDNF induction by HDACIs is not
yet fully understood. Surprisingly, HDAC4 reduction had no
effect on global transcriptional dysfunction and did not mod-
ulate nuclear huntingtin aggregation in HD mousse models
(Mielcarek et al., 2013a). Interestingly, elevated HDAC4 levels
have been shown in post mortem HD (Yeh et al., 2013) and FTLD
(Frontotemporal Lobar Degeneration) (Whitehouse et al., 2014)
brains and HDAC4 has been described as a component of Lewy
Bodies in Parkinson’s disease brains (Takahashi-Fujigasaki and
Fujigasaki, 2006) and of intranuclear inclusions in the neuronal
intranuclear inclusion disease (Takahashi-Fujigasaki et al., 2006).
Consistently, administration of SAHA has been shown to improve
synaptic plasticity and learning behavior in an Alzheimer dis-
ease model (Kilgore et al., 2010). A causative role for HDAC4
has been also described in SCA-1 (Spinocerebellar Ataxia Type
1) as a modulator of Ataxin-1. It was shown that ataxin-1 bound
specifically to HDAC4 and MEF2 and co-localized with them
in the nuclear inclusion bodies. Significantly, these interactions
were greatly reduced by the S776A mutation, which largely abro-
gates the cytotoxicity of ataxin-1 in vitro (Bolger et al., 2007).
Moreover, HDAC4 has been found to be significantly overex-
pressed in specific cortical regions of autistic patients (Nardone
et al., 2014).
Diabetes is one of major risk factors for dementia. However,
the molecular mechanism underlying the risk of diabetes for
dementia is largely unknown. Surprisingly, it has been shown
that diabetes may cause epigenetic changes in the brain, which
adversely affect synaptic function. These alterations were associ-
ated with an increased susceptibility to oligomeric Aβ-induced
synaptic impairments in the hippocampal structure that even-
tually led to synaptic dysfunction. Use of pharmacological
inhibitors against the HDAC IIa family restored synaptic function
(Wang et al., 2014b). This therapeutic effect highlights the impor-
tance of HDACIIa members, including HDAC4, as a possible
target in the brain.
CONCLUSION
There is convincing evidence suggesting that HDAC4 plays a cen-
tral role in the brain physiology and that it is deregulated in
several neurodegenerative disorders, therefore representing a suit-
able therapeutic target, through which HDACs inhibition may
occur. However, the use of currently available HDACIs is likely
to involve adverse side effects due to the broad spectrum HDAC
inhibition. Therefore, a search for selective HDAC inhibitors
would likely be of benefit for targeted therapy. Likely, HDACs
inhibition occurs through a dual mechanism, either by a direct
inhibition of an active deacetylase domain (class I, IIb, III, and
IV) or by a direct binding followed by proteosomal degradation
(class IIa) (Figure 2). Crucially, relatively little is known regard-
ing individual HDACs functions in the adult brain. Although,
class I HDACs biological functions have been intensively stud-
ied in the brain, it appears that suitable HDAC targets could
arise from HDAC IIa subfamily but their function and role are
still poorly understood. Recent studies identified HDAC4 as a
critical component of several neurological processes including
neuronal survival and synaptic plasticity in healthy and diseased
brains. However, little is known about HDAC4 cellular process
like: mechanisms governing HDAC4 cellular localization, post-
translational modification and a proteolytic cleavage, especially
in the diseased brains. In addition, HDAC4 transcriptional reg-
ulation has not been studied and therefore the description of
the specific transcription factors and regulatory elements driving
HDAC4 expression should be carefully undertaken. The presence
of an inactive deacetylase domain within the class IIa HDACs
might also suggest that newly designed small molecules should
be rather directed to the HDAC4 known functions, including
transcription binding domain, HDAC3 interaction or proteolytic
cleavage sites than toward deacetylase domain. Therefore, much
more research is needed to fully describe biological function of
HDAC4 in the healthy and diseased brains to be able to shape
future therapeutic strategies for a various disorders.
FIGURE 2 | A general mechanism of HDACIs (HDAC Inhibitors) action.
Class I (HDACs: 1, 2, 3, 8), Class IIa (HDACs: 4, 5, 7, 9), Class IIb (HDACs: 6,
10), Class III (sirtuins 1-7), and Class IV (HDAC11).
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